

# Clinical trials of FAC

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>facilitated stenting vs alteplase</b>			
<b>STOPAMI 1 , 2000</b> n=71/69 follow-up: 6 months	stent plus abciximab versus intravenous alteplase	patients with acute myocardial infarction	Parallel groups open

More details and results :

- myocardial revascularization for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q129>
- PCI for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q246>

## References

### STOPAMI 1, 2000:

Schmig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neumann FJ, Schwaiger M Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000;343:385-91 [[10933737](#)]

## 2 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>Multiple risk factor interventions vs control</b>			
<b>CELL , 1995</b> n=339/320 follow-up: 18 months	intensive" health care advice through six group sessions versus usual care	subjects aged 30-59 years, with at least two cardiovascular risk factors in addition to moderately high lipid concentrations: total cholesterol $\geq$ 6.5 mmol/l on three occasions, triglycerides $<$ 4.0 mmol/l, and ratio of low density lipoprotein cholesterol to high density lipoprotein cholesterol $>$ 4.0	Factorial plan open

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>Family Heart , 1994</b> n=3436/5912 follow-up: 1 y	Nurse led programme using a family centred approach with follow up according to degree of risk. Counselling on diet, weight, smoking, exercise, alcohol versus control	men aged 40-59 and their partners	Parallel groups double-blind UK
<b>Gteborg Study , 1986</b> n=10004/20018 follow-up: 11.8 yr	multifactorial intervention programme on coronary heart disease versus no intervention	random sample of men age 47-55 y	open Sweden
<b>HDFP , 1979</b> [NCT00000498] n=5485/5455 follow-up: 5 yr	Stepped care: Antihypertensive drugs, diet, smoking advice, weight control, exercise versus usual primary care	persons with high blood pressure	Parallel groups open USA
<b>Helsinki Businessmen Study , 1985</b> n=612/610 follow-up: 5 yr	Multifactorial prevention of cardiovascular diseases versus no intervention	healthy men 40-58 y at high risk	Parallel groups open Finland
<b>Johns Hopkins , 1983</b> n=350/50 follow-up: 5 yr	health education interventions versus control	hypertensives men and women	Factorial plan open USA
<b>Meland , 1997</b> n=69/58 follow-up: 1 y	patient-centred, self-directive intervention of lifestyle changes in general practice versus conventional care	men with high coronary heart disease risk	Parallel groups open
<b>MRFIT , 1982</b> [NCT00000487?acronym=] n=6428/6438 follow-up: 6 yr	special intervention (SI) program consisting of stepped-care treatment for hypertension, counseling for cigarette smoking, and dietary advice for lowering blood cholesterol levels versus no intervention	high-risk men aged 35 to 57 years	Parallel groups open
<b>Oslo , 1981</b> n=612/610 follow-up: 5 yr	recommendation to lower their blood lipids by change of diet and to stop smoking versus no intervention	healthy, normotensive men at high risk of coronary heart disease	Parallel groups open Oslo, Norway

continued...

Trial	Treatments	Patients	Trials design and methods
<b>OXCHECK , 1994</b> n=8307/2783 follow-up: 3 yr	health checks by nurses versus no intervention	patients from general practice aged 35-64 years	Parallel groups open UK
<b>WHO Factories , 1982</b> n=30489/26971 follow-up: 6 years	multifactorial prevention of coronary heart disease versus no intervention	men employed in 80 factories in Belgium, Italy, Poland, and the UK	Parallel groups open Belgium, Italy, Poland, and the UK

More details and results :

- lifestyle intervention for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q282>
- lifestyle intervention for cardiovascular prevention in primary prevention at <http://www.trialresultscenter.org/go-Q447>

## References

### CELL, 1995:

Lindholm LH, Ekbom T, Dash C, Eriksson M, Tibblin G, Scherstn B The impact of health care advice given in primary care on cardiovascular risk. CELL Study Group. BMJ 1995;310:1105-9 [[7742677](#)]

Lindholm LH, Ekbom T, Dash C, Isacson A, Scherstn B Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study. J Intern Med 1996;240:13-22 [[8708586](#)]

### Family Heart, 1994:

Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. Family Heart Study Group. BMJ 1994;308:313-20 [[8124121](#)]

### Gteborg Study, 1986:

Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert K, Vedin A, Wilhelmsson C, Werk L The multifactor primary prevention trial in Gteborg, Sweden. Eur Heart J 1986;7:279-88 [[3720755](#)]

### HDFP, 1979:

Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979;242:2562-71 [[490882](#)]

### Helsinki Businessmen Study, 1985:

Miettinen TA, Huttunen JK, Naukkarinen V, Strandberg T, Mattila S, Kumlin T, Sarna S Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality. JAMA 1985;254:2097-102 [[4046137](#)]

Strandberg TE, Salomaa VV, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettinen TA Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1991;266:1225-9 [[1870247](#)]

Strandberg TE, Salomaa VV, Vanhanen HT, Naukkarinen VA, Sarna SJ, Miettinen TA Mortality in participants and non-participants of a multifactorial prevention study of cardiovascular diseases: a 28 year follow up of the Helsinki Businessmen Study. Br Heart J 1995;74:449-54 [[7488463](#)]

### Johns Hopkins, 1983:

Morisky DE, Levine DM, Green LW, Shapiro S, Russell RP, Smith CR Five-year blood pressure control and mortality following health education for hypertensive patients. *Am J Public Health* 1983;73:153-62 [6849473]

### Meland, 1997:

Meland E, Laerum E, Ulvik RJ Effectiveness of two preventive interventions for coronary heart disease in primary care. *Scand J Prim Health Care* 1997;15:57-64 [9101627]

Meland E, Maeland JG, Laerum E The importance of self-efficacy in cardiovascular risk factor change. *Scand J Public Health* 1999;27:11-7 [10847665]

### MRFIT, 1982:

Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. The Multiple Risk Factor Intervention Trial Research Group. *JAMA* 1990;263:1795-801 [2179590]

Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. *JAMA* 1982;248:1465-77 [7050440]

### Oslo, 1981:

Anderssen S, Holme I, Urdal P, Hjerermann I Diet and exercise intervention have favourable effects on blood pressure in mild hypertensives: the Oslo Diet and Exercise Study (ODES). *Blood Press* 1995;4:343-9 [8746601]

Hjerermann I, Holme I, Leren P Oslo Study Diet and Antismoking Trial. Results after 102 months. *Am J Med* 1986;80:7-11 [3511692]

Hjerermann I, Velve Byre K, Holme I, Leren P Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. *Lancet* 1981;2:1303-10 [6118715]

Holme I, Hjerermann I, Helgeland A, Leren P The Oslo Study: diet and antismoking advice. Additional results from a 5-year primary preventive trial in middle-aged men. *Prev Med* 1985;14:279-92 [3903733]

### OXCHECK, 1994:

Effectiveness of health checks conducted by nurses in primary care: results of the OXCHECK study after one year. Imperial Cancer Research Fund OXCHECK Study Group. *BMJ* 1994;308:308-12 [8124120]

### WHO Factories, 1982:

European collaborative trial of multifactorial prevention of coronary heart disease: final report on the 6-year results. World Health Organisation European Collaborative Group. *Lancet* 1986;1:869-72 [2870351]

Multifactorial trial in the prevention of coronary heart disease: 2. Risk factor changes at two and four years. *Eur Heart J* 1982;3:184-90 [7084265]

## 3 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
fibroblast growth factor vs placebo			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>FIRST (Simons) , 2002</b> n=NA follow-up: 90 days	Single-bolus intracoronary administration of fibroblast growth factor-2 (FGF2) versus placebo	patients with coronary artery disease	double blind
<b>fibroblast growth factor gene vs placebo</b>			
<b>AGENT 3 and 4 pooled</b> n=NA follow-up:	-	-	
<b>AGENT-1 (Grines) , 2002</b> n=NA follow-up:	-	-	
<b>AGENT-2 (Grines) , 2003</b> n=NA follow-up:	-	-	
<b>AGENT-3</b> [NCT00346437] n=NA follow-up:	Ad5FGF-4 (replication deficient, E1A/E1Bdeleted, human adenovirus serotype 5 with human FGF-4 gene insert: alferminogene tadenovec versus placebo	-	
<b>AGENT-4</b> [NCT00185263] n=NA follow-up:	Ad5FGF-4 (replication deficient, E1A/E1Bdeleted, human adenovirus serotype 5 with human FGF-4 gene insert: alferminogene tadenovec versus placebo	-	
<b>AWARE</b> [NCT00438867] n=NA follow-up:	intracoronary infusion of Ad5FGF-4 versus placebo	Female Patients With Stable Angina Pectoris Who Are Not Candidates for Revascularization	double blind
<b>vascular endothelial growth factor vs placebo</b>			
<b>VIVA (Henry) , 2003</b> n=NA follow-up: 12 days	intracoronary and intravenous infusions of recombinant human vascular endothelial growth factor protein (rhVEGF) versus placebo	patients with stable exertional angina, unsuitable for standard revascularization	double blind
<b>GCSF Granulocyte-Colony Stimulating Factor vs placebo</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
Seiler <i>ongoing</i> [NCT00886509] n=NA follow-up: 6 months	Subcutaneous Administration of Pegylated Granulocyte-Colony Stimulating Factor versus placebo	patients with stable coronary artery disease treatable by PCI	Parallel groups double blind

More details and results :

- cell-based therapies for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q300>

## References

### FIRST (Simons), 2002:

Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA *Circulation* 2002;105:788-93 [[11854116](#)]

### AGENT 3 and 4 pooled, 0:

### AGENT-1 (Grines), 2002:

Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL *Circulation* 2002;105:1291-7 [[11901038](#)]

### AGENT-2 (Grines), 2003:

Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N *J Am Coll Cardiol* 2003;42:1339-47 [[14563572](#)]

### AGENT-3, 0:

### AGENT-4, 0:

### AWARE, 0:

### VIVA (Henry), 2003:

Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER *Circulation* 2003;107:1359-65 [[12642354](#)]

### Seiler, :

ongoing trial NCT00886509

Entry terms: fibroblast growth factor, tofacitinib, tasocitinib, tofacitinib citrate, Xeljanz, CP690550, CP-690550, CP 690550,